Aegean Trial: Perioperative Durvalumab For Nsclc - Onctalk Lung 2023

AEGEAN Trial: Perioperative Durvalumab for NSCLC - OncTalk Lung 2023

GRACE - Global Resource for Advancing Cancer Education

NEOTORCH Trial: Perioperative Toripalimab for NSCLC - OncTalk Lung 2023

GRACE - Global Resource for Advancing Cancer Education

AEGEAN Study - FDA Approval of Durvalumab in Resectable Non-Small Cell Lung Cancer

OncBrothers: Practice-Changing Cancer Discussions

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC

PeerView Oncology

[lung]The role of durvalumab in patients with stage 3 lung cancer in a real hospital

David Lauren Research | Oncology in 3 minutes.

Refining which patients benefit from consolidation durvalumab for stage III unresectable NSCLC

Perioperative therapies in NSCLC

FDA Approves Durvalumab / Imfinzi for Resectable NSCLC Non-Small Cell Lung Cancer

Stage III NSCLC: When to Start Durvalumab

Phase III real-world PACIFIC-R trial for NSCLC

Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLC

PeerView Oncology

Phase II study of Durvalumab for patients with NSCLC

Dr. Langer on Practice-Changing PACIFIC Data in Stage III NSCLC

How can durvalumab be used in NSCLC?

Immunotherapy in Stage III NSCLC: Practice-Changing Results of PACIFIC Trial (BMIC-006)

EGFRm+ NSCLC: Should We Treat with Durvalumab? - ASCO Lung Review 2022

GRACE - Global Resource for Advancing Cancer Education

Treating for Stage III NSCLC After Progression on Durvalumab

Durvalumab Consolidation in NSCLC: The PACIFIC Trial

Targeted Oncology

Dr. Feldman on Durvalumab for Patients With Lung Cancer